Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer
- PMID: 17404082
- DOI: 10.1158/1078-0432.CCR-06-2701
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer
Abstract
Purpose: To better direct targeted therapies to the patients with tumors that express the target, there is an urgent need for blood-based assays that provide expression information on a consistent basis in real time with minimal patient discomfort. We aimed to use immunomagnetic-capture technology to isolate and analyze circulating tumor cells (CTC) from small volumes of peripheral blood of patients with advanced prostate cancer.
Experimental design: Blood was collected from 63 patients with metastatic prostate cancer. CTCs were isolated by the Cell Search system, which uses antibodies to epithelial cell adhesion marker and immunomagnetic capture. CTCs were defined as nucleated cells positive for cytokeratins and negative for CD45. Captured cells were analyzed by immunofluorescence, Papanicolau staining, and fluorescence in situ hybridization.
Results: Most patients (65%) had 5 or more CTCs per 7.5 mL blood sample. Cell counts were consistent between laboratories (c = 0.99) and did not change significantly over 72 or 96 h of storage before processing (c = 0.99). Their identity as prostate cancer cells was confirmed by conventional cytologic analysis. Molecular profiling, including analysis of epidermal growth factor receptor (EGFR) expression, chromosome ploidy, and androgen receptor (AR) gene amplification, was possible for all prostate cancer patients with >or=5 CTCs.
Conclusions: The analysis of cancer-related alterations at the DNA and protein level from CTCs is feasible in a hospital-based clinical laboratory. The alterations observed in EGFR and AR suggest that the methodology may have a role in clinical decision making.
Similar articles
-
Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis.Prostate. 2008 Jun 15;68(9):919-23. doi: 10.1002/pros.20715. Prostate. 2008. PMID: 18409189
-
Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.Breast Cancer Res Treat. 2009 Dec;118(3):523-30. doi: 10.1007/s10549-009-0461-7. Epub 2009 Jul 12. Breast Cancer Res Treat. 2009. PMID: 19597704
-
Androgen receptor gene amplification and protein expression in recurrent prostate cancer.J Urol. 2003 Nov;170(5):1817-21. doi: 10.1097/01.ju.0000091873.09677.f4. J Urol. 2003. PMID: 14532783
-
Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.BJU Int. 2009 Aug;104(4):438-48. doi: 10.1111/j.1464-410X.2009.08695.x. Epub 2009 Jun 24. BJU Int. 2009. PMID: 19558559 Review.
-
Castration-resistant prostate cancer: locking up the molecular escape routes.Clin Cancer Res. 2009 May 15;15(10):3251-5. doi: 10.1158/1078-0432.CCR-08-1171. Epub 2009 May 15. Clin Cancer Res. 2009. PMID: 19447877 Review.
Cited by
-
Circulating and disseminated tumor cells in the management of advanced prostate cancer.Adv Urol. 2012;2012:135281. doi: 10.1155/2012/135281. Epub 2011 Aug 21. Adv Urol. 2012. PMID: 21869883 Free PMC article.
-
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.J Clin Oncol. 2014 Apr 10;32(11):1136-42. doi: 10.1200/JCO.2013.51.7417. Epub 2014 Mar 10. J Clin Oncol. 2014. PMID: 24616308 Free PMC article. Clinical Trial.
-
A novel approach for detecting viable and tissue-specific circulating tumor cells through an adenovirus-based reporter vector.Prostate. 2014 Sep;74(13):1286-1296. doi: 10.1002/pros.22845. Epub 2014 Jul 25. Prostate. 2014. PMID: 25065656 Free PMC article.
-
AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer.Endocr Relat Cancer. 2021 Aug 11;28(9):645-655. doi: 10.1530/ERC-21-0157. Endocr Relat Cancer. 2021. PMID: 34280123 Free PMC article.
-
Biomarker development in the context of urologic cancers.Urol Oncol. 2015 Jun;33(6):295-301. doi: 10.1016/j.urolonc.2015.01.007. Epub 2015 Mar 5. Urol Oncol. 2015. PMID: 25746942 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous